shutterstock_2269918937_the_image_party
5 October 2023Big PharmaMarisa Woutersen

Genexa sues in clash over 'clean medicine'

Genexa files lawsuit against KinderFarms relating to agave-based over-the-counter pain relief medicines for children | Accuses KinderFarm of ‘willful, intentional, and deliberate’ actions.

Genexa has filed a patent infringement lawsuit against KinderFarms alleging the copying of Genexa’s patented agave-based acetaminophen formulation, filed in the US District Court for the Central District of California.

Genexa is a ‘clean medicine’ company whose formulas use active ingredients alongside natural, often organic, components, avoiding synthetic additives such as artificial colours, flavours, and sweeteners.

The company’s innovation, covered by US patent 11,617,795, is present in over-the-counter medicines that use agave syrup from the agave plant and citrus extract as a natural preservative.

This formulation suspends active pharmaceutical ingredients within the syrup, reducing bitterness and allowing for the addition of natural flavouring agents without the need for artificial additives.

Genexa alleged that KinderFarms infringed its patented formulation and launched products such as KinderMed Kids' Pain & Fever and KinderMed Infants' Pain & Fever, directly competing with Genexa's Kids' Pain & Fever and Infants' Pain & Fever products.

The suit outlined KinderFarms' products claimed to be made with only 2-5 recognisable inactive ingredients, including organic agave syrup, organic flavour, non-GMO citric acid, and purified water.

Genexa is seeking damages and a permanent injunction against KinderFarms for its alleged patent infringement.

The lawsuit argues that KinderFarms' actions are willful, intentional, and deliberate, posing a significant threat to Genexa's business and brand.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 June 2019   American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
Big Pharma
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

More on this story

Big Pharma
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Americas
3 June 2019   American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.

More on this story

Big Pharma
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Americas
3 June 2019   American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.